TP53 and non-small cell lung carcinoma: found that concomitant TP53 mutation status was not associated with relapse-free survival (RFS) or OS in patients with EGFR-mutant NSCLC at an early stage who underwent primary surgical resection and received adjuvant chemotherapy, suggesting that co-mutations were not a strong prognostic marker in early-stage patients without receiving EGFR-TKI therapy (39).